Background-Platelet abnormalities are well-recognized complications of diabetes mellitus. Mitochondria play a central role in platelet metabolism and activation. Mitochondrial dysfunction is evident in diabetes mellitus. The molecular pathway for hyperglycemia-induced mitochondrial dysfunction in platelets in diabetes mellitus is unknown. Methods and Results-Using both human and humanized mouse models, we report that hyperglycemia-induced aldose reductase activation and subsequent reactive oxygen species production lead to increased p53 phosphorylation (Ser15), which promotes mitochondrial dysfunction, damage, and rupture by sequestration of the antiapoptotic protein Bcl-x L .
D
iabetes mellitus (DM) is a complex disease characterized by absolute insulin deficiency or resistance to insulin, leading to hyperglycemia. 1 The altered glucose metabolism can lead to many organ complications, including nephropathy, neuropathy, and retinopathy. 2 Platelet abnormalities are one of the hallmarks of DM, contributing to the pathogenesis of many disease processes, including atherosclerosis and thrombosis. 3 Several mechanisms have been proposed to explain the platelet abnormalities in DM, among which metabolic alterations and oxidative stress appear to play pivotal roles. 4 
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Mitochondrial alterations contribute to the pathogenesis of DM. 5 Given the central role of mitochondria in platelet metabolism and activation, mitochondrial alteration may contribute to platelet abnormalities in DM. Indeed, previous studies using isolated platelets from patients with type 2 DM have demonstrated low mitochondrial membrane potential compared with control subjects 6 and upregulation of antioxidant enzymes (SOD2 and PRDX3), which indicates increased oxidative stress. 7 Therefore, it is plausible that hyperglycemia-induced oxidative stress impairs mitochondrial function in DM platelets. Oxidative stress plays an important role in the development of microvascular and cardiovascular diabetic complications. 8 In platelets, hyperglycemia-induced oxidative stress has been shown to contribute to platelet hyperreactivity. 9, 10 However, the role of hyperglycemia-induced oxidative stress in platelet mitochondrial function is unknown.
Platelets have also been demonstrated to possess critical signaling proteins (Bcl family proteins) known to regulate mitochondria-dependent apoptosis. 11 Pharmacological inhibition of Bcl-x L with the BH3 mimetic compounds ABT-737 or ABT-263 triggers platelet apoptosis in vitro and acute thrombocytopenia in vivo, [12] [13] [14] which suggests that Bcl-x L plays a crucial role in regulating the mitochondria-dependent apoptosis in platelets. ABT-737 treatment causes platelet mitochondrial damage with concomitant activation of caspase 3, which consequently leads to externalization of phosphatidylserine.
Despite these elegant studies demonstrating the presence of many stress and apoptosis signaling components, the pathway connecting these signaling components to hyperglycemia and mitochondrial damage, as well as their consequences in DM platelets, is not known.
We hypothesized that aldose reductase (AR) plays a key role in the pathway leading from hyperglycemia to platelet mitochondrial damage. AR, the first key enzyme in the polyol pathway, is well known to contribute to oxidative stress in DM. 16 AR contributes to platelet activation and to hyperactivation in platelets under hyperglycemia. 9, 17 In the present study, we aimed to investigate the role of AR in diabetes-mediated mitochondrial dysfunction, as well as the signaling pathways involved in this process. We demonstrate that AR contributes to diabetes-mediated mitochondrial dysfunction and damage through the activation of p53. We report that the degree of mitochondrial dysfunction and damage determines whether hyperactivity (mild damage) or apoptosis (severe damage) will ensue.
Methods
A more detailed description of the Methods can be found in the online-only Data Supplement.
Patient Recruitment and Preparation of Human Platelet Samples
Venous blood was drawn from consenting volunteers (healthy and DM subjects) at Yale University School of Medicine (Human Investigation Committee No. 1005006865). Sixty-six subjects with type 2 DM (American Diabetes Association definition) and 8 healthy control subjects (HS) were recruited for the studies (online-only Data Supplement Table I ). The platelet-rich plasma and washed platelets were collected by centrifugation.
Development of Mouse Model for DM With Human AR Expression
Mice were injected with streptozotocin (50 mg/kg) intraperitoneally for 5 consecutive days to induce DM. Four weeks after streptozotocin administration, mice were maintained on a high-cholesterol diet for 12 weeks. Platelets were collected by centrifugation.
Ligation of Mouse Carotid Artery
The carotid artery ligation model was performed as described previously. 18 Briefly, the left common carotid artery was ligated near the carotid bifurcation. After 7 days, mice were euthanized. The left and right arteries were fixed in 4% paraformaldehyde, embedded in OCT compound, and sectioned for analysis.
Confocal Microscopy
The washed platelets were settled on glass-bottomed dishes for 30 minutes, fixed with 4% paraformaldehyde, and stained with specific antibodies. The stained platelets were observed with a Nikon Eclipse-Ti (Nikon Instruments, Melville, NY) confocal microscope with a 100× oil immersion lens.
Determination of Mitochondrial Membrane Potential, Phosphatidylserine Externalization, and Mitochondrial Superoxide Production
To assess the changes in mitochondrial membrane potential (∆Ψ m ) and phosphatidylserine externalization by use of flow cytometry, platelets were stained with 40 nmol/L tetramethylrhodamine methyl ester (TMRM), followed by staining with 4 μg/mL annexin V. To measure mitochondrial superoxide production, platelets were stained with 5 μmol/L MitoSOX Red (Life Technologies, Carlsbad, CA).
Western Blotting, Immunoprecipitation, and Subcellular Fractionation
Protein samples were subjected to SDS-PAGE, and the proteins were transferred to nitrocellulose membrane and probed with the indicated antibodies. For immunoprecipitation, platelet lysates were incubated with agarose-conjugated p53 antibody, and the immunoprecipitated proteins were eluted in SDS loading buffer for Western blot analysis. Subcellular fractionation was performed with a mitochondria isolation kit (Pierce Biotechnology, Rockford, IL).
Statistical Analysis
All data were expressed as mean±SD. The parametric t test was performed for comparisons of 2 groups. The parametric 1-way ANOVA, followed by Tukey multiple comparison test, was used to assess difference between >2 groups within the same study. Analysis was performed with Prism software (GraphPad Software, Inc, La Jolla, CA). A difference of P<0.05 was considered significant.
Results

Severe Mitochondrial Damage Occurs in DM Platelets
To initially assess mitochondrial function in DM platelets compared with platelets from control subjects, we measured the ∆Ψ m by TMRM staining. TMRM is readily sequestered by the mitochondria, but its fluorescence is rapidly lost when ∆Ψ m is dissipated. Compared with healthy platelets, DM platelets exhibited reduced ∆Ψ m ( Figure 1A ). According to fluorescence-activated cell sorting analysis, only 10% of platelets were TMRM negative in HS. In contrast, ≈80% of DM platelets and platelets treated with ABT-737 (Bcl-2 inhibitor) were TMRM negative ( Figure 1B ). As positive controls, healthy platelets treated with antimycin A and rotenone (inhibitors for mitochondrial complex I and III, respectively) also demonstrated a greater TMRM-negative population ( Figure 1B ). In addition to ∆Ψ m dissipation, mitochondrial superoxide production was increased significantly with rotenone and antimycin A (positive controls; Figure 1C ). Further supporting the severe mitochondrial damage, the mitochondrial permeability transition pore (MPTP) was also increased, as demonstrated by the loss of retained calcein fluorescence in the mitochondria with a cobalt chloride-quenching assay ( Figure I in the online-only Data Supplement). Ionomycin was used as a control to trigger complete MPTP permeability. Using electron microscopy, we also observed direct evidence of mitochondrial damage. The mitochondria from DM platelets exhibited varying degrees of damage and rupture of the outer mitochondrial membrane compared with HS platelets, which predominantly showed the classic double-membrane mitochondria without outer mitochondrial membrane damage ( Figure 1D ). The complete electron microscopy field is provided in Figure IIA in the online-only Data Supplement, and a lower-power field showing distinct morphological differences in HS versus DM platelets is shown in Figure IIB in the online-only Data Supplement. Collectively, these results demonstrate that platelet mitochondrial dysfunction and damage are characteristics of DM platelets.
DM Platelets Exhibit Increased p53 Phosphorylation
To identify the key components that lead to mitochondrial dysfunction in DM platelets, we used a proteome profiler array (R&D Systems, Minneapolis, MN) to compare platelets from HS (n=8 pooled) and patients with type 2 DM (n=8 pooled). The most consistent observation was reduced expression of Bcl-x L by 2.5-fold in DM and, interestingly, increased phosphorylation of p53 at serine 15 by 2-fold ( Figure IIIA In both the cytosolic and mitochondrial fractions of platelets, the expression of p53 and its phosphorylation at serine 15 were markedly upregulated in DM compared with HS, but no detectable changes in Bax and Bak were observed (Figure 2A ). Using high-power confocal microscopy, we demonstrate that in DM platelets, the level of p53 phosphorylated at serine 15 was increased, and much of it localized to the mitochondria, whereas Bcl-x L was diminished ( Figure 2B ). The complete field where these platelets were selected is shown in Figure  IVA in the online-only Data Supplement. In addition to phosphorylation, we found that glutathionylation and acetylation of p53 were increased in DM platelets ( Figure IVB in the online-only Data Supplement).
Previous studies have suggested that p53 can induce mitochondrial opening by interacting with Bcl-xL. 19 Bcl-x L coimmunoprecipitated with p53 increased markedly in DM platelets by 3-fold compared with HS ( Figure 2B ), which can be attributed to phosphorylated p53. Detection was limited in healthy platelets because of low levels of phosphorylated p53 ( Figure 2C ). Together with the colocalization studies from confocal microscopy, our results showed that Bcl-x L was sequestered by the increased phosphorylated p53. In platelets, Bcl-x L exerts its prosurvival reaction by binding to the proapoptotic mediators Bax and Bak at the mitochondria. 20 Therefore, because Bcl-x L is sequestered by phosphorylated p53, Bax and Bak would mediate the outer membrane permeabilization, leading to the release of cytochrome c from the intermembrane space. 21 The loss of cytochrome c in the intermembrane space can no longer inhibit reactive oxygen species formation in the electron transport, which leads to increased oxidative stress and further mitochondrial permeability. 22 In addition to the interaction between p53 and Bcl-x L , recent data have demonstrated that Bcl-x L alone can stabilize the ∆Ψ m by interacting with ATP synthase. 23 ATP synthase activity was not changed in the diabetic platelets ( Figure IA in the online-only Data Supplement). p53 has been associated with regulation of mitochondrial respiration. 24 We found that mitochondrial ATP levels were reduced in diabetic platelets, which suggests that ATP generation from oxidative phosphorylation was impaired in DM platelets. Interestingly, cytosolic ATP was increased in diabetic platelets, which suggests that increased glycolytic flux may ensue in DM platelets ( Figure  IB in the online-only Data Supplement). These findings are supported by a previous study that showed that platelets from patients with type 2 DM are characterized by high levels of total ATP but low ∆Ψ m .
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AR Contributes to Hyperglycemia-Induced p53 Phosphorylation in Human Platelets
To understand whether acute hyperglycemia contributes to p53 phosphorylation, human platelets isolated from HS were incubated with 5 mmol/L glucose or 25 mmol/L glucose (HG) for 2 hours. Platelets incubated with HG showed increased p53 phosphorylation localized to mitochondria ( Figure 3A) ; however, in contrast to DM platelets, no reduction in Bcl-x L expression was observed in normal platelets treated with HG ( Figure 3A) . The increased phosphorylation of p53 at serine 15 was further confirmed by Western blot ( Figure 3B ). In contrast to DM platelets, total p53 expression was not changed after incubation of healthy platelets with HG.
It is well recognized that phosphorylation of p53 at serine 15 is mediated by oxidative stress.
26-28 Therefore, we hypothesized that hyperglycemia-induced oxidative stress (mediated by AR) 16 phosphorylated p53 in platelets, which translocated to the mitochondria with Bcl-x L . 29 Treatment with epalrestat (10 μmol/L), an AR inhibitor (ARI), and the antioxidant Figure 3A and 3B). Treatment with pifithrin-μ, an inhibitor of p53 that binds to mitochondrial Bcl-x L protein, 30 attenuated the interaction with Bcl-x L but had no effect on the phosphorylation of p53 ( Figure 3B and 3C). Treatment with Z-DEVD-FMK (a downstream caspase 3 inhibitor) also showed no effect on the phosphorylation of p53. The binding of Bcl-x L with immunoprecipitated p53 also increased in platelets incubated with HG, which is comparable to DM ( Figure 3C ), which suggests that hyperglycemia enhanced phosphorylation of p53 and protein-protein interaction with Bcl-x L . Treatment with an ARI also attenuated the interaction between Bcl-x L and p53, although the effect was less than with pifithrin-μ ( Figure 3C) .
We have previously shown in human platelets that high glucose can induce the phosphorylation of p38α mitogenactivated protein kinase (MAPK) through AR activity, 9 and it is known that p53 can be phosphorylated by the activation of p38α MAPK. 28, 31 In both DM and HG-treated platelets, the phosphorylation of p38α MAPK was increased, which was attenuated by ARI and SB239063 (a p38α MAPK inhibitor).
Inhibition of p38α MAPK also reduced the HG-induced p53 phosphorylation, which suggests that AR activity increased the phosphorylation of p38α MAPK, leading to p53 activation in human platelets under the HG condition ( Figure 3D ). With regard to mitochondrial function, HG platelets exhibited mild mitochondrial alterations, including reduced ∆Ψ m and MPTP opening. Moreover, annexin V-positive platelets were also increased modestly under the HG condition. All of these changes were attenuated by treatment with ARI or pifithrin-μ ( Figure VA and VB in the online-only Data Supplement). Taken together, the present results demonstrated that a 2-hour hyperglycemia treatment was sufficient to activate p53 and led to mild mitochondrial dysfunction by increasing its phosphorylation and binding to Bcl-x L , and this was caused, at least in part, by AR activation and reactive oxygen species production in platelets.
Platelet Mitochondrial Dysfunction in Transgenic DM Mice Expressing Human AR
Wild-type mice have very little native AR (analogous to a functional knockout). The lack of AR may be a key reason why mice are resistant to the deleterious effect of hyperglycemia. 32 We therefore induced DM in a mouse model in which human AR (huAR) was expressed and had activity comparable to that found in human platelets ( Figure VIA in the online-only Data Supplement). Blood glucose levels were significantly elevated in DM mice, and no significant difference was found in body weight ( Figure VIB in the onlineonly Data Supplement).
Consistent with the findings in DM patients, huAR transgenic murine platelets exhibited dissipation of ∆Ψ m and phosphatidylserine externalization (apoptosis) under DM conditions. A clear reduction in the TMRM-positive population and significant increases in the annexin V-positive population were also observed in mouse platelets treated with ABT-737 10 μmol/L ( Figure 4A ). Likewise, mitochondrial superoxide and MPTP opening were increased significantly in DM murine platelets ( Figure 4B and 4C) . All of these results suggested that mitochondrial function is severely altered in DM murine platelets where cellular apoptosis occurs.
We further studied whether phosphorylation of p53 at serine 15 was also found in DM murine platelets. Consistent with our findings in human platelets, the expression of p53 and its phosphorylation at serine 15 was increased in DM murine platelets ( Figure 4D ). Expression of Bcl-x L was reduced and caspase 3 activation and cytochrome c release were increased in DM murine platelets. Confirming our human data, the subcellular level of Bax and Bak was not changed in DM murine platelets compared with non-DM murine platelets ( Figure 4E ). Together, these mouse studies further validate our observations in human platelets, in which mitochondrial function is altered in DM platelets, likely from AR-dependent activation of p53. Moreover, platelet apoptosis may ensue.
AR Contributes to Acute Hyperglycemia-Induced Mitochondrial Dysfunction by Increasing P53 Phosphorylation in Non-DM Murine Platelets
To further understand how AR contributes to hyperglycemiainduced mitochondrial alterations, huAR transgenic murine platelets (non-DM) were subjected to different concentrations of glucose for 2 hours. For incubation with HG, ∆Ψ m was significantly dissipated with concomitant phosphatidylserine externalization in huAR transgenic murine platelets in a dose-dependent manner, and the effect was markedly attenuated by the treatment with an ARI ( Figure 5A ). The opening of the MPTP also increased with treatment with glucose 25 mmol/L and was restored by treatment with an ARI ( Figure 5B ). This further supports a role of AR as a key player in hyperglycemia-induced mitochondrial dysfunction. Consistent with mitochondrial dysfunction, phosphorylation of p53 at serine 15 was increased significantly in murine platelets incubated with glucose 25 mmol/L, which was attenuated by AR inhibition ( Figure 5C ). Taken together, our results demonstrate that huAR expression in murine platelets exacerbates hyperglycemia-induced mitochondrial dysfunction through p53 activation.
Platelet Activation and Apoptosis Are Distinct States in DM Human Platelets
In DM human platelets, the dissipation of ∆Ψ m is so severe that there is a concomitant increase in phosphatidylserine externalization ( Figure 6A ). Such severe mitochondrial damage and apoptosis were visible as a paucity of red staining (dissipation of ∆Ψ m ) inside the green rings (phosphatidylserine externalization) when the platelets were stained with TMRM. Treatment with ABT-737 10 μmol/L was also found to reduce ∆Ψ m and increase phosphatidylserine externalization ( Figure 6A ). Also, compared with HS, a larger population of annexin V-positive platelets (apoptotic platelets) was found in both DM platelets and platelets treated with ABT-737 (3% versus 30% and 70%, respectively; Figure 6B ). Using fluorescence-activated cell sorting analysis, we also showed that DM platelets exhibited an increase in the apoptotic population compared with HS platelets in a glucose (in vivo) dose-dependent manner ( Figure 6C ). Consistent with severe mitochondrial dysfunction and phosphatidylserine externalization, active caspase 3 and cytochrome c release were also increased in the DM platelets ( Figure 6D and 6E) .
Because both activation and apoptosis can ensue in DM platelets, we sought to understand the role of mitochondrial dysfunction in platelet activation. Platelets were divided into high ∆Ψ m (red population) and low ∆Ψ m (blue population) according to TMRM fluorescence with flow cytometry. Platelet activation in response to ADP 1 μmol/L can be demonstrated by an increase in size and a shape change of the cell population to a narrower, elongated shape. 33 Platelet activation was observed in the red population of platelets incubated with either 5 or 15 mmol/L glucose and in DM platelets, which suggests that platelets with high ∆Ψ m contribute to platelet activation. However, ABT-737-treated platelets exhibited primarily a blue population, so platelet activation in the red population was not found ( Figure Data Supplement). These findings indicate distinct pools of platelets arising from hyperglycemia. Depending on the severity of the mitochondrial damage caused by hyperglycemia, platelets with a large decrease in ∆Ψ m do not respond to agonist stimulation (apoptotic platelets), but those with a mild decrease in ∆Ψ m (active platelets) or no decrease in ∆Ψ m (normal platelets) were able to respond to ADP stimulation. Thus, mitochondrial dysfunction appears to play a central role in determining platelet activation or apoptosis under conditions of hyperglycemia.
Diabetes-Induced Platelet Hyperreactivity Leads to Arterial Thrombosis
It is well established that DM platelets can be hyperactive, as demonstrated by our aggregation studies in human platelets ( Figure VIII in the online-only Data Supplement). Previous studies have shown that increased platelet apoptosis, as indicated by increased phosphatidylserine externalization, leads to increased procoagulant activity, which enhances thrombosis in rat. 34 Moreover, apoptosis induces increased platelet turnover, and the ensuing larger, younger platelets are more active, 35 which further contributes to increased thrombosis. To further study the role of AR in platelet function in vivo, carotid artery ligation was performed in our mouse model, and thrombus formation was assessed by hematoxylin-andeosin and immunofluorescent staining. After 7-day carotid artery ligation (blood stasis model), thrombus formation was increased under DM conditions, particularly in the presence of huAR ( Figure 7A and 7B ). Platelet deposition, as determined by platelet marker CD41 staining, was also increased in huAR mice compared with nontransgenic mice ( Figure 7C ). Under non-DM conditions, thrombus formation was not increased significantly in huAR mice compared with nontransgenic mice. Platelets from DM mice showed increased aggregation in response to collagen 10 μg/mL, and platelet aggregation was increased in huAR mice compared with nontransgenic mice (Figure 7D ). These results support that huAR expression contributes to DM-induced platelet hyperreactivity and apoptosis, which leads to increased arterial thrombosis.
Discussion
We demonstrate for the first time that AR-mediated p53 phosphorylation contributes to ∆Ψ m dissipation, MPTP activation, and mitochondrial dysfunction, damage, and rupture in DM platelets (Figure 8 ). This can result in caspase 3 activation and phosphatidylserine externalization in DM human platelets, features typical of apoptosis. These mechanistic studies provide new insights into platelet abnormalities and potential therapy (eg, ARIs) in DM to prevent cardiovascular complications.
We were surprised to discover that p53 played an important role in hyperglycemia-mediated platelet mitochondria dysfunction. In addition to its role in transcription, p53 has been demonstrated to have a direct apoptogenic role at the mitochondria. 19 In the present study, hyperglycemia-induced 
by guest on May 11, 2017 http://circ.ahajournals.org/ Downloaded from phosphorylation of p53 at serine 15 was also found to contribute to mitochondrial dysfunction, which was significantly attenuated by treatment with ARI and the antioxidant N-acetylcysteine. Reactive oxygen species production is an early event in p53-induced mitochondrial damage. [36] [37] [38] AR activity can induce phosphorylation of p38α MAPK by increasing oxidative stress under hyperglycemic conditions, 9,39,40 which leads to phosphorylation of p53. 28, 31 Consistent with these studies, the present results showed that pharmacological inhibition of p38α MAPK attenuated the phosphorylation of p53 under hyperglycemia, which indicates that AR activity contributes to phosphorylation of p53 through the oxidative stress and activation of p38α MAPK.
Bcl-x L plays a central role in the regulation of platelet survival. 13 Moreover, loss of Bcl-x L results in thrombocytopenia. 41 Consistent with previous studies that showed Bcl-x L can be downregulated in various DM tissues, [42] [43] [44] we also found that expression of Bcl-x L was reduced in DM platelets but not in acute hyperglycemia. The present study and another 29 now demonstrate that p53 phosphorylated at serine 15 can translocate into mitochondria and sequester Bcl-x L , leading to dissipation of ∆Ψ m. These results in human platelets showed that AR contributed to p53 phosphorylation and its binding to Bcl-x L through hyperglycemia-induced oxidative stress, which led to mitochondrial damage (Figure 8 ).
It has been suggested previously that platelet activation and apoptosis are closely related, because ∆Ψ m dissipation, caspase 3 activation, and phosphatidylserine externalization have been found with thrombin-stimulated platelets. 45 Previous studies showed that activation of Bax (a proapoptotic protein that physically targets mitochondria) 46 generates a subpopulation of highly activated platelets, which suggests that mitochondria and Bcl-2 family proteins participate in the process of platelet activation and mitochondrial damage and apoptosis. Therefore, it is plausible that mitochondrial alteration and the resultant apoptotic signaling (caspase 3 activation and phosphatidylserine externalization) are triggered in DM platelets, contributing to thrombus formation. Indeed, patients with type 2 DM exhibit platelet hyperreactivity both in vitro and in vivo, coupled with biochemical evidence of persistently increased thromboxane-dependent platelet activation, 47 accelerated turnover of platelets, 48 increased platelet apoptosis, and excessive thrombus formation. 49 Consistent with such studies, we provide evidence that both platelet activation and apoptosis ensue in DM platelets, and these 2 distinct processes are dependent on the activity of AR and the resultant mitochondrial damage. Phosphatidylserine externalization promotes thrombin formation, 50 a marker for procoagulant activity. Moreover, with increased apoptosis, increasing numbers of younger platelets are released, and these larger, younger platelets are more active. 35 Taken together, the present findings suggest that both platelet activation and apoptosis synergistically contribute to increased thrombosis in DM.
Currently, more than 19.7 million adults (8.3%) in the United States have diagnosed DM, and 38.2% of the US adult population has prediabetes. 51 Sixty-five percent of patients with DM will die of thrombotic cardiovascular events in which platelets play key roles. 52 Of great concern is that 10% to 40% of patients with DM are biochemically resistant to aspirin, the drug most commonly used to prevent and treat heart attacks and strokes. 52, 53 New therapies targeting the underlying mechanism for platelet dysfunction are urgently warranted. On the basis of our studies, we now propose that drugs targeting platelet AR/reactive oxygen species/p53 may be effective against hyperglycemia-induced platelet dysfunction.
Study Limitations
The inherent fragile nature of platelets, particularly those from DM patients, required that studies be performed within a few hours of blood acquisition, and thus, many DM patient recruits were required; however, the reproducibility and consistency from the use of 66 heterogeneous patients with DM adds strength to our conclusions. Inherent differences are known to exist between mouse and human platelets, particularly because mouse platelets lack AR. However, conferring p53 induction and mitochondrial sensitivity by overexpressing human AR supports the importance of this hyperglycemiainduced signaling mechanism. 
Human platelet preparation
Platelet rich plasma was prepared by differential centrifugation of 27 ml of blood drawn by venipuncture into 3 ml of 3.8% trisodium citrate (w/v). Platelet-poor plasma (PPP) was obtained by centrifugation at 1400 g (25°C for 10 min). PRP was adjusted with PPP to 2-3 × 10 8 platelets/ml. For washed platelets, the platelets were washed twice and resuspended at 2-3 × 10 8 platelets/ml.
Development of mouse model for DM with human AR expression
To develop mice that mimic human subjects with high cardiovascular risk, huAR-LDLR -/-mice with human AR (huAR) transgene expression on a C57BL/6J background (B6.Cg-Ldlr tm1Her Tg(H2-K-AKR1B1)1Tj/J; stock no. 006877 ) were purchased from Jackson Labs. To study the effects of recurrent episodes of hyperglycemia on platelets rather than single high glucose treatment, we induced DM in mice using streptozotocin (STZ).
Eight week old mice were divided into 2 groups; one half were injected with STZ (50 mg/kg) intraperitoneally for 5 days to induce recurrent episodes of acute hyperglycemia (DM), and the other half were used as non-DM controls. Four weeks after STZ administration, DM and non-DM mice were maintained on high cholesterol diet (HCD) for 12 weeks, fasted 6 hours and sacrificed for blood sampling. Glucose was measured from the tail-tip with a glucometer.
The Institutional Animal Care and Use Committee at Yale University approved all animal protocols (IACUC #11413 & #11539).
Murine platelet preparation
Blood (0.7-1 mL) was directly aspirated from the right cardiac ventricle into 1.8% sodium citrate (pH 7.4). Citrated blood from several mice of identical genotype was pooled, and diluted with equal volume of HEPES/Tyrode's buffer. PRP was prepared by centrifugation at 100 g for 10 min and then used for measuring platelet aggregation in response to 10 µg/ml of collagen. Washed platelets were prepared from PRP by centrifugation at 5000 g for 2 mins. The platelet pellets were resuspended in HEPES/Tyrode's buffer in the presence of 3 μg/mL apyrase.
Ligation of mouse carotid artery
The left common carotid artery was partially ligated near the carotid bifurcation. All mice recovered from surgery and showed no symptoms of stroke. Mice were euthanized seven days after carotid artery ligation. Left and right arteries were fixed in 4%
paraformaldehyde. Arteries were embedded in OCT compound, and serial sections (5 µm thick) were cut for analysis by hematoxylin-eosin staining and immunofluorescent staining.
Five sections spanning most of the vessel segments from each mouse were analyzed for morphometry.
Confocal microscopy
Washed platelets were allowed to settle on glass-bottom dishes for 30 min before fixing for 15 mins with 4% paraformaldehyde in PBS. After fixation, platelets were permeabilized for 10 minutes using 0.5% triton-X 100 in PBS with 3% BSA, and incubated with different After washing, the immunoprecipitated proteins were eluted in SDS loading buffer for Western analysis. Quantification of Bcl-x L binding to p53 was performed using Image Lab software.
